Intercept shares more than double in pre-market after NASH primary endpoint met Shares of Intercept Pharmaceuticals are up about 140% to $173.00 in pre-market trading after the company announced that the FLINT trial of obeticholic acid, or OCA, for the treatment of nonalcoholic steatohepatitis, or NASH, has been stopped early for efficacy based on a planned interim analysis showing that the primary endpoint of the trial has been met. Intercept closed trading yesterday at $72.39.
News For ICPT From The Last 14 Days
Check below for free stories on ICPT the last two weeks.
Intercept feedback positive, says BofA/Merrill BofA/Merrill's recent discussions with NASH liver expert believes Intercept's OCA path to market may be straight forward and not require CV outcomes data prior to approval and that FLINT study will have a positive impact on the NASH resolution. The firm reiterates its Buy rating and $872 price target.